Literature DB >> 11216854

Induction of P-glycoprotein mRNA transcripts by cycloheximide in animal tissues: evidence that class I Pgp is transcriptionally regulated whereas class II Pgp is post-transcriptionally regulated.

C H Lee1.   

Abstract

P-glycoprotein (Pgp) are a small family of plasma membrane proteins capable of transporting substrates across cell membranes. Class I and class II Pgp are able to transport drugs and have been shown to mediate multidrug resistance (MDR). Class III Pgp is a long chain phospholipid transporter and does not mediate MDR. The expression and regulation of Pgp genes in animal tissues are not well understood. In this study, the protein synthesis inhibitor cycloheximide was used as a tool to understand Pgp gene expression and regulation in animal tissues. The sensitive RNase protection assay was used to detect changes in Pgp mRNA levels and nuclear run-on assay was used to determine whether transcription or post-transcription is important. The results showed that cycloheximide significantly induced class II Pgp expression in all tissues examined. This was predominantly through post-transcriptional effect. In contrast, the relatively modest increase in class I Pgp expression by cycloheximide was found to be mainly due to increased transcriptional activity. On the other hand, cycloheximide induced class III Pgp expression in some tissues while caused decay of class III Pgp mRNA in other tissues. The transcriptional and post-transcriptional mechanisms exerted by cycloheximide on Pgp genes are discussed. These findings have implications for our understanding of gene regulation in animal tissues and MDR reversal strategies in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11216854     DOI: 10.1023/a:1011086716568

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  52 in total

Review 1.  mRNA degradation. A tale of poly(A) and multiprotein machines.

Authors:  A J Carpousis; N F Vanzo; L C Raynal
Journal:  Trends Genet       Date:  1999-01       Impact factor: 11.639

Review 2.  Multidrug resistance: molecular mechanisms and clinical relevance.

Authors:  V Ling
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

Review 3.  The physiological function of drug-transporting P-glycoproteins.

Authors:  A H Schinkel
Journal:  Semin Cancer Biol       Date:  1997-06       Impact factor: 15.707

Review 4.  A hypothesis to explain why translation inhibitors stabilize mRNAs in mammalian cells: mRNA stability and mitosis.

Authors:  J Ross
Journal:  Bioessays       Date:  1997-06       Impact factor: 4.345

Review 5.  Hepatic canalicular membrane 4: expression of the multidrug resistance genes in the liver.

Authors:  J A Silverman; D Schrenk
Journal:  FASEB J       Date:  1997-04       Impact factor: 5.191

6.  MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.

Authors:  A van Helvoort; A J Smith; H Sprong; I Fritzsche; A H Schinkel; P Borst; G van Meer
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

7.  Characterization of the basal and carcinogen regulatory elements of the rat mdr1b promoter.

Authors:  J A Silverman; B A Hill
Journal:  Mol Carcinog       Date:  1995-05       Impact factor: 4.784

8.  Cellular pattern of multidrug-resistance gene expression during chemical hepatocarcinogenesis in the rat.

Authors:  H Nakatsukasa; R P Evarts; R K Burt; P Nagy; S S Thorgeirsson
Journal:  Mol Carcinog       Date:  1992       Impact factor: 4.784

9.  Posttranscriptional regulation of cyclin B messenger RNA expression in the regenerating rat liver.

Authors:  J H Trembley; B T Kren; C J Steer
Journal:  Cell Growth Differ       Date:  1994-01

10.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

Authors:  K V Chin; K Ueda; I Pastan; M M Gottesman
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

View more
  3 in total

1.  De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.

Authors:  Jianjiang Ye; Lyndle Gradoville; Derek Daigle; George Miller
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

Review 2.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.

Authors:  S Eyal; J G Lamb; M Smith-Yockman; B Yagen; E Fibach; Y Altschuler; H S White; M Bialer
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.